Colon Cancer Clinical Trials

178 recruitingLast updated: June 17, 2026

There are 178 actively recruiting colon cancer clinical trials across 33 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Los Angeles, California, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Colon Cancer Trials at a Glance

178 actively recruiting trials for colon cancer are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Not Applicable with 70 trials, with the heaviest enrollment activity in Los Angeles, New York, and Boston. Lead sponsors running colon cancer studies include National Cancer Institute (NCI), Chongqing Precision Biotech Co., Ltd, and Dana-Farber Cancer Institute.

Browse colon cancer trials by phase

Treatments under study

About Colon Cancer Clinical Trials

Looking for clinical trials for Colon Cancer? There are currently 117 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Colon Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Colon Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 178 trials

Recruiting
Not Applicable

Family Communications After Genetic Testing

Stage IV Colorectal Cancer AJCC v8Stage I Colorectal Cancer AJCC v8Stage II Colorectal Cancer AJCC v8+12 more
Alliance for Clinical Trials in Oncology4,186 enrolled242 locationsNCT07143487
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Colorectal, CancerOvarian CancerLung Cancer+17 more
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting
Phase 2

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

Colon CancerdMMR Colorectal Cancer
University of Iowa25 enrolled2 locationsNCT05239546
Recruiting
Phase 2

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

Colorectal, CancerColon CancerRectal Cancer+1 more
SCRI Development Innovations, LLC60 enrolled14 locationsNCT07011576
Recruiting
Phase 1

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Breast CancerCervical CancerColon Cancer+4 more
Orano Med Theranostics, SAS48 enrolled8 locationsNCT05283330
Recruiting
Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

Colorectal, CancerColon CancerCRC+4 more
Cartography Biosciences80 enrolled8 locationsNCT07321106
Recruiting

Leakage Rate of Ileo-COlic Sutured Anastomosis After Right Hemicolectomy

Colon CancerAnastomotic LeakRight Hemicolectomy
Aesculap AG249 enrolled4 locationsNCT07132970
Recruiting

Genomic Services Research Program

Breast CancerColon Cancer
National Human Genome Research Institute (NHGRI)5,000 enrolled1 locationNCT02595957
Recruiting

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

Breast CancerLiver CancerProstate Cancer+2 more
National Cancer Institute (NCI)750 enrolled1 locationNCT00451022
Recruiting
Phase 1

A Study of PHN-012 in Patients With Advanced Solid Tumors

Pancreatic CancerColon CancerAdvanced Cancer+2 more
Pheon Therapeutics165 enrolled20 locationsNCT07127874
Recruiting
Not Applicable

Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)

Ovarian CancerColon CancerRectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle50 enrolled1 locationNCT07098182
Recruiting
Phase 2Phase 3

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Stage III Colon Cancer
NRG Oncology1,912 enrolled1061 locationsNCT05174169
Recruiting

Collection of Blood From Patients With Cancer

Breast CancerLiver CancerProstate Cancer+2 more
National Cancer Institute (NCI)1,750 enrolled1 locationNCT00034216
Recruiting
Phase 1Phase 2

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Pancreatic CancerGastric CancerColon Cancer+2 more
National Cancer Institute (NCI)110 enrolled1 locationNCT03190941
Recruiting
Not Applicable

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

Liver CancerEsophageal CancerColon Cancer+7 more
Case Comprehensive Cancer Center200 enrolled1 locationNCT06263088
Recruiting
Not Applicable

Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis

Liver Metastasis Colon CancerLiver SteatosesNAFLD
Anton Skaro124 enrolled1 locationNCT05884723
Recruiting
Phase 2

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Gastric CancerColon CancerMSI-H+1 more
Peking University34 enrolled1 locationNCT06580574
Recruiting
Early Phase 1

Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases

Stage, Colon CancerStage I-III Colon CancerStage IV Colon Cancer With Resectable Liver Metastases
Dana-Farber Cancer Institute80 enrolled1 locationNCT02172651
Recruiting
Phase 1

Brodalumab in the Treatment of Immune-Related Adverse Events

Breast CancerLiver CancerEsophageal Cancer+15 more
Brian Henick, MD11 enrolled1 locationNCT06673329
Recruiting
Not Applicable

Adaptive Symptom Self-Management Immunotherapy Study

Breast CancerLung CancerColon Cancer+2 more
University of Arizona400 enrolled3 locationsNCT05715255